The Patented Medicines Prices Review Board (PMPRB) launched its new website earlier this week.
Features of the new website include:
A new look
Enhanced functionality and accessibility
A scalable, mobile-friendly format
The PMPRB stresses that the content of the website will remain the same and further information regarding these changes will be released ... Read More
02
Oct2014
02
Oct2014
The Régie de l’assurance maladie du Québec (RAMQ) has released its October update of the List of Medications, which constitutes a regulatory list of the medications covered by Québec's basic prescription drug insurance plan.
For more information and to see the list update schedule, please visit the RAMQ website.
18
Sep2014
The Patented Medicine Prices Review Board (PMPRB) recently announced that they will be launching a new website by the end of September.
Features of the new website include:
A new look
Enhanced functionality and accessibility
A scalable, mobile-friendly format
The PMPRB stresses that the content of the website will remain the same and further information ... Read More
16
Sep2014
Yesterday, thePMPRB released its Annual Reportfor the year ending December 31, 2013. The Annual Report is an extensive document that reviews all of the PMPRB´s major activities, analyses of the prices of patented medicines and of the price trends of all drugs, and reports on the R&D expenditures as reported by ... Read More
16
Sep2014
The Canadian Agency for Drugs and Technologies in Health (CADTH) revised its Guidelines for Manufacturers on Application Fees for the Common Drug Review. A draft version was circulated for stakeholder feedback in July, following which the below key changes were made:
Fees for resubmission based on new clinical information ... Read More
18
Aug2014
The C-MAP™ Canadian Drug Benefit Plans Reference Guide is the authoritative source for comprehensive and up-to-date information on Canadian reimbursement and market access for pharmaceutical market access specialists. The publication highlights each of the relevant agencies, organizations and drug plans operating in the market access and reimbursement environment in Canada. ... Read More
06
Aug2014
Direct-Acting Antivirals for Chronic Hepatitis C Genotype 1: Draft recommendations posted, feedback requested
Yesterday the Canadian Agency for Drugs and Technologies in Health (CADTH)posted on its website the draft Canadian Drug Expert Committee (CDEC) recommendations report stemming from itsrecent therapeutic review project to assess the clinical and economic impact ... Read More
05
Aug2014
Included in this edition are:
New Board Member Appointed (Carolyn Kobernick)
Staffing Changes
Sylvie Dupont’s retirement
Guillaume Couillard joins the PMPRB (new Director of the Board Secretariat, Communications and Strategic Planning)
Appointments:
Tanya Potashnik (Director of the Policy and Economic Analysis Branch)
Elena Lungu (Manager of the National Prescription Drug Utilization Information System (NPDUIS))
Decisions in Cases: ratio-Salbutamol, ... Read More
31
Jul2014
The Canadian Agency for Drugs and Technologies in Health (CADTH) is requesting stakeholder feedback on its draft guidance document, released today, concerning its recent announcement to introduce industry application fees for manufacturer submissions and resubmissions made to the Common Drug Review.
The draft Guidelines for Manufacturers on Application Fees ... Read More
30
Jul2014
An updated table with the targeted Canadian Drug Expert Committee (CDEC) meeting dates is now available on the CADTH website
A CDEC meeting will be held in December 2014 as part of an initiative to eliminate an accumulation of CDR submissions.
CADTH is extending the pilot process for receiving patient input ... Read More